Plain-English translation of NCT07198854 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a research study looking back at patients who received mesenchymal stem cell (MSC) infusions for a serious liver condition called acute-on-chronic liver failure caused by hepatitis B. The goal is to figure out which patients benefited most from this stem cell treatment and which ones did not, so doctors can predict in the future who is most likely to improve with this therapy.
Stem cell treatment shows promise for this severe liver condition, but not all patients respond equally well. By identifying what factors predict success or failure, doctors hope to better select which patients will truly benefit from this treatment and how to improve outcomes for others.
You likely qualify if…
You likely don't qualify if…
This is a retrospective study, meaning researchers will review your existing medical records from your hospital visits between 2010 and 2018. You would not receive any new treatment or make additional clinic visits for this study. The research team will collect information about your liver function, survival, and any complications you experienced after receiving stem cell infusions.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China
Enrollment target
~446 participants
Started
October 2025
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dr. Chen
Sun Yat-sen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.